Project Grant R21CA288943
Award Date 8/18/25
Completion Date 7/31/27
Dollars Obligated $395K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $398,997 Project Grant under CFDA Program 93.395 (Cancer Treatment Research) to Immunogenik, Inc. located in Gainesville, FL. The funding will support research aimed at enhancing cancer immunotherapies by targeting tumor-associated myeloid cells (TAMCs) such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs). The research focuses on the role of the leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) in...
- The University of Florida was awarded a $540,288 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on May 1, 2025. The purpose of this 5-year grant is to investigate the role of bacterial-derived small molecules in improving the efficacy of immune checkpoint inhibitor (ICI) treatment for non-small cell lung cancer (NSCLC) patients. The research aims to identify specific bacteria from ICI-responsive patients that produce small molecules capable of...
- This Project Grant, awarded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), focuses on developing antibody blockade targeting a novel immune checkpoint, LAIR1/CD305, to overcome inhibition by tumor-associated macrophages and enhance cancer immunotherapy. The $398,997 award to Immunogenik, Inc., a minority-owned small business in Florida, aims to validate a clinical-grade anti-LAIR1 antibody through in vitro studies and conduct efficacy studies in tumor-bearing mice. The...
- The National Cancer Institute (NCI) awarded a $549,962 Project Grant under the Cancer Biology Research federal grant program (CFDA 93.396) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The 5-year grant, which began on April 1, 2025, will support research to determine how antibodies and cellular ligands regulate the immunosuppressive function of the protein Lymphocyte-Activation Gene 3 (LAG3). This project aims to address gaps in the understanding of...
- This $549,460 federal Project Grant award, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. aimed at understanding the biology, transcriptional programs, and epigenetic control of CD8+ tumor infiltrating lymphocytes (TILs) and their progression to a terminally exhausted state. The research will also investigate tumor memory CD8+ T cells, their response, transcriptional...
- This federal Project Grant award of $421,685 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research to investigate the "reactive" immune system in tumors and the tumor microenvironment. The primary objective is to discover discrete niches within the tumor microenvironment that are conducive to anti-tumor immunity, in order to guide the development of more effective cancer immunotherapies. The research approach combines spatial...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research aimed at understanding how different forms of cell death, particularly programmed necrosis, can alter the immune response and impact tumor growth. The $568,538 award to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. will fund a 5-year study to investigate the role of the cytokine interleukin-1 alpha in mediating immune suppression and promoting...
- This $162,486 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) is supporting a research project at the University of Miami to develop a novel immunotherapy for pancreatic cancer using microRNA-29a. The key objectives are to determine how microRNA-29a regulates T-cell dysfunction in pancreatic cancer and evaluate its potential to overcome resistance to immune checkpoint blockade therapies. The research leverages the university's...
- This federal Project Grant award of $2,628,974.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research to enhance the understanding of dendritic cell (DC) migration and its impact on DC vaccine efficacy through an innovative nanotechnology-enabled imaging technology called Magnetic Particle Imaging (MPI). The research aims to develop quantitative, non-invasive MPI techniques that can longitudinally track DC vaccines and capture the...
- This $149,804 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research to investigate the impact of the LAG3 protein on CD8+ T cell motility and migration in the context of cancer immunotherapy. The research aims to elucidate the mechanism by which LAG3 restricts T cell motility and determine if LAG3 impacts CD8+ T cell infiltration and interactions within the tumor microenvironment. The project is being conducted by the University...